-$0.98 Earnings Per Share Expected for KemPharm Inc (KMPH) This Quarter

Share on StockTwits

Equities analysts expect KemPharm Inc (NASDAQ:KMPH) to announce earnings of ($0.98) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for KemPharm’s earnings. The highest EPS estimate is ($0.86) and the lowest is ($1.18). KemPharm posted earnings per share of ($0.44) during the same quarter last year, which suggests a negative year over year growth rate of 122.7%. The company is expected to issue its next quarterly earnings report on Thursday, August 9th.

On average, analysts expect that KemPharm will report full-year earnings of ($4.11) per share for the current financial year, with EPS estimates ranging from ($4.41) to ($3.68). For the next year, analysts forecast that the business will report earnings of ($2.78) per share, with EPS estimates ranging from ($3.47) to ($2.10). Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for KemPharm.

KemPharm (NASDAQ:KMPH) last announced its quarterly earnings results on Thursday, May 10th. The specialty pharmaceutical company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.41).

A number of brokerages recently commented on KMPH. Zacks Investment Research lowered KemPharm from a “buy” rating to a “hold” rating in a research note on Friday, March 30th. ValuEngine raised KemPharm from a “sell” rating to a “hold” rating in a research note on Friday, April 6th. Canaccord Genuity set a $11.00 price target on KemPharm and gave the company a “buy” rating in a research note on Friday, February 23rd. Finally, Oppenheimer reissued a “buy” rating on shares of KemPharm in a research note on Thursday, March 22nd. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $11.21.

Shares of KemPharm stock opened at $6.05 on Friday. KemPharm has a 12 month low of $2.45 and a 12 month high of $8.40. The company has a market cap of $90.25 million, a P/E ratio of -2.04 and a beta of -0.19. The company has a debt-to-equity ratio of -1.13, a current ratio of 2.83 and a quick ratio of 2.83.

In related news, EVP Daniel L. Cohen acquired 7,900 shares of the stock in a transaction dated Tuesday, May 15th. The stock was acquired at an average cost of $6.45 per share, with a total value of $50,955.00. Following the purchase, the executive vice president now directly owns 35,500 shares of the company’s stock, valued at $228,975. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 25.90% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of the company. Royal Bank of Canada lifted its stake in shares of KemPharm by 1,847.1% in the 1st quarter. Royal Bank of Canada now owns 24,125 shares of the specialty pharmaceutical company’s stock valued at $191,000 after purchasing an additional 22,886 shares during the last quarter. Millennium Management LLC bought a new stake in shares of KemPharm in the 1st quarter valued at approximately $122,000. Change Path LLC bought a new stake in shares of KemPharm in the 1st quarter valued at approximately $479,000. JPMorgan Chase & Co. lifted its stake in shares of KemPharm by 15,976.2% in the 1st quarter. JPMorgan Chase & Co. now owns 100,637 shares of the specialty pharmaceutical company’s stock valued at $795,000 after purchasing an additional 100,011 shares during the last quarter. Finally, ING Groep NV bought a new stake in shares of KemPharm in the 1st quarter valued at approximately $1,102,000. 36.49% of the stock is owned by institutional investors and hedge funds.

KemPharm Company Profile

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply